Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Next Previous
Trial Profile

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Rezatapopt (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms PYNNACLE
  • Sponsors PMV Pharmaceuticals

Most Recent Events

  • 06 Mar 2026 According to a PMV Pharmaceuticals media release, New findings from this PYNNACLE Phase 2 trial in ovarian cancer were presented at the 2026 European Society of Gynecologic Oncology Congress.
  • 26 Feb 2026 According to a PMV Pharmaceuticals media release, In October 2025, the Company presented updated interim clinical results from the Phase 2 pivotal portion of the PYNNACLE study.
  • 26 Feb 2026 According to a PMV Pharmaceuticals media release, data from the trial were presented in the New England Journal of Medicine (NEJM).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top